Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

BACKGROUND: Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody. Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma. OBJECTIVE: We explored whether benra...

Descripción completa

Detalles Bibliográficos
Autores principales: FitzGerald, J Mark, Bleecker, Eugene R, Bourdin, Arnaud, Busse, William W, Ferguson, Gary T, Brooks, Laura, Barker, Peter, Martin, Ubaldo J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910092/
https://www.ncbi.nlm.nih.gov/pubmed/31849500
http://dx.doi.org/10.2147/JAA.S227170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910092/
https://www.ncbi.nlm.nih.gov/pubmed/31849500
http://dx.doi.org/10.2147/JAA.S227170

Ejemplares similares